Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Por um escritor misterioso
Descrição
Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.
FDA approves Bayer's Nubeqa® (darolutamide), a new treatment for
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival
The Hospitalization-Related Costs of Adverse Events for Novel
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival
Prostate Cancer Treatment (PDQ®) - PDQ Cancer Information
ARVib suppresses growth of advanced prostate cancer via inhibition
Understanding the Current Therapeutic Landscape for Advanced
Cells, Free Full-Text
Effect of crossover from placebo to darolutamide on overall
Prostate cancer Nature Reviews Disease Primers
Darolutamide and Survival in Metastatic, Hormone-Sensitive
